Loading...
Loading chart...





The current price of MYMD is 0 USD — it has increased 0 % in the last trading day.
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Wall Street analysts forecast MYMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYMD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Mymd Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.
Mymd Pharmaceuticals Inc. EPS for the last quarter amounts to 0.06 USD, decreased -166.67 % YoY.
Mymd Pharmaceuticals Inc (MYMD) has 9 emplpoyees as of January 30 2026.
Today MYMD has the market capitalization of 4.00M USD.